Inaktiver Wert

Andere Sprachen Myovant Sciences Ltd.

Aktien

A2DFYA

BMG637AM1024

MYOV

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Sumitomo Pharma Unit Closes $1.7 Billion Purchase of Myovant Sciences	14.03.23
MYOVANT SCIENCES LTD. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events (form 8-K)	10.03.23
Myovant Sciences Ltd.(NYSE:MYOV) dropped from S&P Biotechnology Select Industry Index	10.03.23
Myovant Sciences Ltd.(NYSE:MYOV) dropped from S&P TMI Index	10.03.23
Myovant Sciences Ltd.(NYSE:MYOV) dropped from S&P Global BMI Index	10.03.23
Sumitovant Biopharma Ltd. completed the acquisition of remaining 47.83% stake in Myovant Sciences Ltd..	10.03.23
MYOVANT SCIENCES LTD. : Submission of Matters to a Vote of Security Holders (form 8-K)	01.03.23
LifeSci Index Partners	28.02.23
Myovant Sciences: Fiscal Q3 Earnings Snapshot	26.01.23
MYOVANT SCIENCES LTD. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	26.01.23
Myovant Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	26.01.23
Earnings Flash (MYOV) MYOVANT SCIENCES Reports Q3 Revenue $100.2M	26.01.23
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022	26.01.23
MYOVANT SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Myovant Sciences - MYOV	25.01.23
Insider Sell: Myovant Sciences	20.01.23
MYOVANT SCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Myovant Sciences - MYOV	12.01.23
Lyell Immunopharma Names Lynn Seely as Chief Executive	15.12.22
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08	16.11.22
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08	16.11.22
Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources	16.11.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Myovant Sciences Ltd.

Aktien

A2DFYA

BMG637AM1024

MYOV

Andere Sprachen

Filter